Anebulo Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Anebulo Pharmaceuticals has been growing earnings at an average annual rate of 29.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
29.9%
Earnings growth rate
44.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -417.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Anebulo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -8 | 5 | 4 |
| 30 Jun 24 | 0 | -8 | 5 | 4 |
| 31 Mar 24 | 0 | -9 | 5 | 4 |
| 31 Dec 23 | 0 | -10 | 6 | 5 |
| 30 Sep 23 | 0 | -12 | 6 | 6 |
| 30 Jun 23 | 0 | -12 | 6 | 6 |
| 31 Mar 23 | 0 | -12 | 6 | 5 |
| 31 Dec 22 | 0 | -11 | 6 | 5 |
| 30 Sep 22 | 0 | -8 | 4 | 3 |
| 30 Jun 22 | 0 | -7 | 4 | 3 |
| 31 Mar 22 | 0 | -34 | 3 | 4 |
| 31 Dec 21 | 0 | -41 | 3 | 3 |
| 30 Sep 21 | 0 | -40 | 2 | 3 |
| 30 Jun 21 | 0 | -38 | 1 | 2 |
Quality Earnings: 214 is currently unprofitable.
Growing Profit Margin: 214 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 214 is unprofitable, but has reduced losses over the past 5 years at a rate of 29.9% per year.
Accelerating Growth: Unable to compare 214's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 214 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 214 has a negative Return on Equity (-417.21%), as it is currently unprofitable.